Eton Pharmaceuticals, Inc.
ETONNASDAQHealthcare● Active
$29.95
+$0.82(+2.81%)
Market Cap$820401122
P/E Ratio—
52W High$35.66
52W Low$13.09
Eton Pharmaceuticals, Inc. (ETON) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ETON · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.05
Est. $0.10 · -50.0%
Revenue
$0.02B
Est. $0.02B · +8.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ETON reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.13 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 14, 2026 | $0.10 | $0.05 | -50.0% | $0.02B | $0.02B | +8.8% |
| ▼ Q1 FY2026 | Mar 19, 2026 | $0.12 | $0.05 | -58.3% | $0.02B | $0.02B | +6.5% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $0.16 | -$0.07 | -143.8% | $0.02B | $0.02B | +9.7% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.01 | -$0.10 | -900.0% | $0.02B | $0.02B | -7.5% |
| ▼ Q2 FY2025 | May 13, 2025 | $0.09 | $0.07 | -22.2% | $0.02B | $0.02B | +14.2% |
| — Q1 FY2025 | Mar 18, 2025 | -$0.02 | -$0.02 | +0.0% | $0.01B | $0.01B | -18.7% |
| ▲ Q4 FY2024 | Nov 12, 2024 | $0.00 | $0.02 | +400.0% | $0.01B | $0.01B | -2.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
$0.05
EPS Est.
$0.10
EPS Surpr.
-50.0%
Revenue
$0.02B
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
$0.05
EPS Est.
$0.12
EPS Surpr.
-58.3%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.07
EPS Est.
$0.16
EPS Surpr.
-143.8%
Revenue
$0.02B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.01
EPS Surpr.
-900.0%
Revenue
$0.02B
Q2 FY2025
May 13, 2025Miss
EPS Actual
$0.07
EPS Est.
$0.09
EPS Surpr.
-22.2%
Revenue
$0.02B
Q1 FY2025
Mar 18, 2025
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$0.02
EPS Est.
$0.00
EPS Surpr.
+400.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.68 | $0.74 | $0.79 | 1 |
| Q3 FY2028 | $0.61 | $0.66 | $0.70 | 1 |
| Q2 FY2028 | $0.53 | $0.57 | $0.61 | 1 |
| Q1 FY2028 | $0.42 | $0.45 | $0.48 | 1 |
| Q4 FY2027 | $0.47 | $0.51 | $0.54 | 1 |
| Q3 FY2027 | $0.48 | $0.52 | $0.55 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.0B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -50.0% | $30.82 | $29.96 | -2.79% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -58.3% | $19.02 | $20.77 | +9.20% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -143.8% | $19.25 | $19.14 | -0.57% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -900.0% | $15.26 | $15.26 | +0.00% |
| ▼ Q2 FY2025 | May 13, 2025 | -22.2% | $17.35 | $17.07 | -1.61% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +0.0% | $15.29 | $14.68 | -3.99% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +400.0% | $9.71 | $9.17 | -5.56% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -71.4% | $3.49 | $3.62 | +3.72% |
Q2 FY2026-2.79%
Report Date
May 14, 2026
EPS Beat/Miss
-50.0%
Price Before
$30.82
Price After
$29.96
Q1 FY2026+9.20%
Report Date
Mar 19, 2026
EPS Beat/Miss
-58.3%
Price Before
$19.02
Price After
$20.77
Q4 FY2025-0.57%
Report Date
Nov 6, 2025
EPS Beat/Miss
-143.8%
Price Before
$19.25
Price After
$19.14
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-900.0%
Price Before
$15.26
Price After
$15.26
Q2 FY2025-1.61%
Report Date
May 13, 2025
EPS Beat/Miss
-22.2%
Price Before
$17.35
Price After
$17.07
Q1 FY2025-3.99%
Report Date
Mar 18, 2025
EPS Beat/Miss
+0.0%
Price Before
$15.29
Price After
$14.68
Q4 FY2024-5.56%
Report Date
Nov 12, 2024
EPS Beat/Miss
+400.0%
Price Before
$9.71
Price After
$9.17
Q3 FY2024+3.72%
Report Date
Aug 8, 2024
EPS Beat/Miss
-71.4%
Price Before
$3.49
Price After
$3.62
Avg Beat Reaction-4.78%
Avg Miss Reaction+1.32%
Beat Rate2 / 8 quarters
Largest Move+9.20% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ETON ends December
Eton Pharmaceuticals, Inc. (ETON) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.05 — missing the analyst consensus of $0.10 by -50.0%. The next ETON earnings date is expected around September 1, 2026.
Each quarter, investors track ETON earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ETON revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ETON's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ETON earnings · 5 questionsEton Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ETON typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ETON historically reports after market close (AMC).
ETON earnings datewhen is ETON earningsETON next earnings datewhen does ETON report earningsETON earnings calendar
▸ Source: FMP · Eton Pharmaceuticals, Inc. SEC filings · US GAAP · Eton Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026